Dr Reddy’s rises on receiving approval for Doxorubicin Hydrochloride Liposome Injection launch

17 May 2017 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 2733.15, up by 10.05 points or 0.37% from its previous closing of Rs. 2723.10 on the BSE.

The scrip opened at Rs. 2717.00 and has touched a high and low of Rs. 2757.00 and Rs. 2690.00 respectively. So far 23588 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2525.25 on 12-May-2017.

Last one week high and low of the scrip stood at Rs. 2,757.00 and Rs. 2525.25 respectively. The current market cap of the company is Rs. 45301.35 crore.

The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 42.95% and 13.87% respectively.

Pharma major Dr Reddy’s Laboratories has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the United States market.

USFDA approval is an outcome of extensive collaboration with the company's partner, Natco Pharma, on R&D and manufacturing capabilities. According to IMS Health, the Doxil brand and generic had U.S. sales of approximately $196 million MAT for the most recent twelve months ending in March 2017.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1218.40 9.95 (0.82%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×